Market Minds Advisory
Rare NRG1 Fusion Market

Rare NRG1 Fusion Market: Companion Diagnostic Expansion and the Tumor-Agnostic Treatment Transition

Rising comprehensive genomic profiling adoption and tumor-agnostic regulatory approval pathways are pushing oncology developers toward NRG1 fusion-targeted therapies, forcing legacy chemotherapy-first treatment protocols to rebuild entirely around biomarker-driven, evidence-backed patient selection criteria.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.4BMarket Size 2025
2036 FORECAST VALUE$1.7BBase Case , 2026 to 2036
CAGR 2026 TO 203614.6 %Bull 15.9% / Bear 13.1%
INCREMENTAL OPPORTUNITY$1.3BNet 10- year value creation
EXPANSION MULTIPLE3.89x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Rare NRG1 fusion treatment demand is shifting from broad-spectrum chemotherapy toward biomarker-targeted therapeutics, as oncology centers increasingly specify comprehensive genomic profiling capable of identifying NRG1 fusion-positive patients across every tumor type served today by academic and community programmes alike.
Bispecific NRG1-HER3 targeted antibodies are growing at roughly 1.47x the market average as oncology centers pursue tumor-agnostic treatment pathways for this ultra-rare genomic alteration. North America retains the largest revenue base on dense comprehensive genomic profiling infrastructure and established precision oncology reimbursement pathways, while East Asia is compounding fastest as China's expanding genomic testing capacity and oncology drug approval pathways pull treatment demand into the category nationwide.
Competitive intensity concentrates among five diversified oncology therapeutics companies that increasingly bundle targeted therapy development, companion diagnostic partnerships, and patient identification support into a single treatment pathway, leaving smaller regional developers to compete on price for standard chemotherapy protocols. Clinical trial evidence depth and companion diagnostic validation, not treatment pricing alone, increasingly determine which suppliers win multi-year oncology center contracts.
Market Definition
The rare NRG1 fusion market covers therapeutics, companion diagnostics, and clinical support services used to identify and treat cancers driven by neuregulin-1 gene fusion alterations, spanning bispecific NRG1-HER3 targeted antibodies, small molecule pan-HER inhibitors, companion diagnostic testing panels, comprehensive genomic profiling services, patient identification and navigation programmes, and clinical trial and real-world evidence services. Broad-spectrum chemotherapy and non-genomically targeted oncology treatments are excluded from market scope.
Base Year Value
$0.4B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
14.6% base case. Bull 15.9%. Bear 13.1%.
Fastest Growth Segment
Bispecific NRG1-HER3 Targeted Antibodies: 21.5% CAGR
Fastest Growth Country
China: 17.8% CAGR
Fastest Growth Region
South Asia and Pacific: 16.5% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
Merus NV, Elevation Oncology Inc, Bicara Therapeutics Inc, Foundation Medicine Inc, Guardant Health Inc. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Rare NRG1 Fusion Market Forecast Scenarios

rare-nrg1-fusion-market-size-forecast-scenario-1787309755461
Between 2020 and 2025 the market grew at an estimated 13.4% historical CAGR, expanding steadily as broader genomic screening adoption identified a growing population of fusion-positive patients across major oncology research hubs throughout the historical period. Companies investing early in bispecific antibody development captured a disproportionate share of this accelerating demand base ahead of slower-moving competitors.
The base case assumes 14.6% CAGR through 2036, anchored in three commercial mechanisms: expanding next-generation sequencing screening adoption across major developed and emerging markets identifying more fusion-positive patients requiring proportional treatment capacity, rising clinical validation of bispecific and pan-HER inhibitor mechanisms sustaining base treatment demand, and growing companion diagnostic partnership development pulling more oncology centers into genomically guided treatment protocols. Regulatory approval momentum across multiple jurisdictions adds a further reinforcing tailwind as the category matures.
A bull scenario, near 15.9% CAGR, assumes faster regulatory approval and accelerated companion diagnostic adoption pull premium treatment volume forward across more tumor types worldwide. The bear case, near 13.1% CAGR, assumes clinical trial delays or narrower approval scope than expected constrain treatment access to a smaller subset of the genomically eligible patient population industry-wide.

Genomic Profiling Adoption Reshapes Treatment Specification Standards

Three forces are converging on rare NRG1 fusion treatment demand simultaneously: expanding comprehensive genomic profiling adoption requiring proportional companion diagnostic testing capacity, rising tumor-agnostic regulatory approval pathways sustaining base treatment demand, and growing patient identification programme investment pushing oncology centers toward systematic biomarker screening. Oncology centers that once tested for NRG1 fusion only in specific tumor types now specify comprehens
MARKET CONCENTRATION71%Combined revenue share held by top five fusion therapeutics companies
AVERAGE TREATMENT COST$195,000Blended average annual cost per patient on targeted therapy
TOP PRESCRIBING COUNTRYUnited StatesLeading country for total fusion-targeted treatment prescription revenue
GENOMIC PROFILING COVERAGE38%Share of eligible advanced cancer patients receiving comprehensive testing
FUSION DETECTION RATE0.2%Blended prevalence of the fusion across profiled solid tumor samples
TREATMENT RESPONSE RATE64%Blended objective response rate across leading targeted therapeutics
Commercially, the category increasingly resembles a diagnostic and treatment partnership bundled around patient identification and clinical evidence support rather than a transactional drug purchase. Oncology centers and therapeutics companies commit to recurring multi-year relationships spanning genomic testing, treatment access, and real-world evidence generation, since fragmenting these functions across multiple providers creates patient identification gaps that a unified relationship avoids.
Over the next decade, expect bispecific antibody and next generation targeted formats to keep gaining share within the broader precision oncology budget as clinical evidence accumulates and genomic testing costs decline, continued consolidation among smaller regional developers unable to fund companion diagnostic partnerships, and growing scrutiny of treatment response outcomes driving faster adoption cycles across major oncology centers worldwide.
"NRG1 fusion used to be a genomic curiosity buried in a pathology report nobody acted on because there was no targeted drug to prescribe. Now that a bispecific antibody exists, that same rare alteration triggers a completely different treatment pathway, and that shift from incidental finding to actionable biomarker has completely changed what oncology centers are willing to test for."
Director, Precision Oncology and Genomic Medicine Practice · MMA Precision Oncol

Market Trends

Oncology Centers Shift Toward Systematic Genomic Screening

Comprehensive cancer centers and community oncology networks are increasingly adopting systematic comprehensive genomic profiling for advanced solid tumors, replacing what were historically targeted single-gene testing protocols applied only after standard treatments failed across most advanced cancer categories served today. Each new systematic screening commitment requires diagnostic suppliers to demonstrate consistent fusion detection accuracy alongside existing panel capabilities, an evidence bar that has tightened considerably over the past several years. Centers completing successful screening adoption report meaningfully improved rare alteration detection rates, reinforcing systematic profiling as the standard specification for new diagnostic investment nationwide and internationally.
Market Impact: Adds 4,200 annual identified patien

Tumor-Agnostic Approval Pathways Standardize Treatment Access

Regulatory agencies and oncology centers are increasingly embracing tumor-agnostic approval pathways that authorize NRG1-targeted therapeutics based on genomic alteration rather than tumor site alone, replacing what were historically tumor-specific approval requirements that limited treatment access for rare fusion-positive patients outside approved indications. Each new tumor-agnostic commitment requires therapeutics companies to demonstrate reliable efficacy data across diverse tumor types alongside existing safety capabilities, an evidence expectation that has tightened over the past several years. Regulatory agencies completing expanded approvals report meaningfully improved patient access speed, reinforcing biomarker-based approval as the standard pathway for new treatment investment.
Market Impact: Adds 17% to tumor-agnostic volume

Market Opportunities and Growth Drivers

Comprehensive Genomic Profiling Adoption Drives Base Demand

Expanding comprehensive genomic profiling adoption across major developed and emerging markets continues driving surging rare NRG1 fusion treatment demand, proportionally expanding requirements for testing capable of serving a broad range of tumor categories across both established lung cancer applications and expanding pancreatic and other solid tumor applications. Companies report that oncology centers increasingly expect dedicated fusion-validated formats specifically for their patient identification requirements rather than relying on generic single-gene testing alone. This profiling growth is expanding the addressable treatment market well beyond the traditional lung cancer categories that historically drove most category demand across the wider oncology supply chain.
Market Impact: Limits addressable population to 0.

Tumor-Agnostic Regulatory Pathways Sustain Base Demand

Continued expansion of tumor-agnostic regulatory approval pathways across major developed and emerging markets is sustaining steady demand for both established and next generation treatment formats required to reach increasingly broad rare fusion-positive patient populations without traditional tumor-specific approval limitations. Companies report that dedicated tumor-agnostic partnerships can meaningfully reduce delayed treatment access cost that far exceeds the incremental cost of upgraded companion diagnostic investment. This regulatory growth is expanding the addressable treatment market well beyond the developed markets that historically drove most category demand, pulling emerging oncology hubs into the buying pool for the first time.
Market Impact: Limits 46% of eligible patients

Market Restraints and Challenges

Ultra-Rare Prevalence Limits Addressable Patient Population

Rare NRG1 fusion treatments carry meaningful exposure to the alteration's ultra-rare prevalence, and the root cause is that NRG1 fusion occurs in a small fraction of solid tumors, meaning even comprehensive genomic profiling expansion identifies a limited absolute patient population relative to broader precision oncology categories with higher alteration frequency. The commercial impact falls hardest on therapeutics companies building commercial infrastructure sized for larger patient populations, since the addressable market ceiling can represent a substantial constraint on achievable revenue relative to development investment. Companies are mitigating this by pursuing tumor-agnostic indications that maximize the addressable population across tumor types.
Market Impact: Lifts systematic screening adoption

Genomic Testing Access Gaps Limit Patient Identification

Rare NRG1 fusion treatment suppliers face meaningful genomic testing access gaps that limit patient identification, and the root cause is that comprehensive genomic profiling remains unavailable or unreimbursed in many community oncology settings where the majority of advanced cancer patients receive care rather than academic centers with established profiling infrastructure. The commercial impact falls hardest on therapeutics companies seeking broad patient identification, since testing access gaps can represent a substantial share of eligible patients never identified relative to the addressable population comprehensive profiling would reveal. Companies are mitigating this by funding community oncology testing access programmes and payer engagement initiatives.
Market Impact: Lifts tumor-agnostic access 19%
3 additional market trends, 4 additional growth drivers, and 4 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows treatment modality and diagnostic function, the single dimension oncology centers specify against when structuring a rare NRG1 fusion procurement decision. Antibody, inhibitor, diagnostic, and support formats each serve a distinct clinical function, keeping treatment and diagnostic dimensions cleanly separate across every oncology category served worldwide by centers, patients, and payers alike.
rare-nrg1-fusion-market-market-share-analysis-1787309755985

Bispecific NRG1-HER3 Targeted Antibodies

Bispecific NRG1-HER3 targeted antibodies bind simultaneously to NRG1 and HER3 receptor targets to disrupt the signaling pathway driving tumor growth in fusion-positive cancers, providing a mechanism-specific treatment approach that broad-spectrum chemotherapy cannot replicate. Adoption is concentrated among comprehensive cancer centers and academic oncology programmes seeking access to next generation targeted therapy for patients identified through genomic profiling. Growth outpaces the broader market by roughly 1.47x as clinical evidence accumulates and oncology centers increasingly prioritize mechanism-specific treatment alongside standard supportive care. Companies with proven clinical trial evidence are capturing outsized share, since building trust in a new targeted therapy brand requires sustained response data most tumor boards are reluctant to adopt without demonstrated performance.
CAGR 21.5%

Companion Diagnostic Testing Panels

Companion diagnostic testing panels use next generation sequencing technology to detect NRG1 fusion alterations alongside other actionable genomic markers, enabling oncologists to identify eligible patients for targeted therapy at the point of initial tumor profiling. Adoption is concentrated among comprehensive cancer centers and reference laboratories seeking to meet growing precision oncology testing demand across major developed markets. Growth remains strong as targeted therapy approvals expand and oncologists increasingly view comprehensive panels as a meaningful driver of treatment matching accuracy beyond single-gene testing alone. Companies completing expanded panel validation report meaningfully improved oncology center retention, reinforcing comprehensive companion diagnostics as a standard specification within premium precision oncology programmes across major cancer center networks worldwide.
CAGR 16.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America retains the largest revenue base on dense comprehensive genomic profiling infrastructure and established precision oncology reimbursement pathways, while East Asia is compounding fastest as China's expanding genomic testing capacity pulls demand into the category nationwide today.

North America

United States comprehensive cancer centers, concentrated around major academic oncology research hubs, anchor the region's demand base as dense genomic profiling infrastructure and established precision oncology reimbursement pathways drive proportional targeted treatment demand across the clinical pathway. Canadian cancer centers continue steady adoption tied to established public healthcare procurement systems covering major regional oncology markets. Broadening comprehensive genomic profiling coverage across major private and public payer programmes continues accelerating patient identification well ahead of many international peer markets facing less developed reimbursement infrastructure. Growth trails East Asia and South Asia because the region's treatment installed base is comparatively larger and more mature relative to the expanding testing investment driving growth elsewhere in the forecast.
Share: 32% | CAGR: 14.3% (2026 to 2036)

Western Europe

German and French comprehensive cancer centers, operating under some of the world's most established oncology drug approval and reimbursement frameworks, sustain steady demand for both diagnostic and treatment formats tied to national and European Union precision medicine regulation. United Kingdom National Health Service oncology programmes continue expanding genomic profiling investment tied to growing precision medicine coverage targets. Regional therapeutics distributors maintain strong domestic penetration built on established oncology center procurement relationships across the continent. Regional growth trails East Asia and South Asia as the market's already established profiling penetration limits the incremental upside further testing investment expansion alone can provide relative to less mature markets elsewhere in the forecast ahead.
Share: 23% | CAGR: 13.2% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
rare-nrg1-fusion-market-country-cagr-analysis-1787309756494

Monetizing Patient Identification and Evidence Generation

Companies are shifting commercial models toward patient identification partnership programmes, real-world evidence generation service contracts, and multi-year testing bundling agreements rather than one-time treatment sales, since oncology center demand for ongoing identification and evidence support now rivals raw treatment pricing as a vendor selection criterion. This mirrors a broader shift across specialty oncology categories toward relationship-based structures.

Offering Patient Identification Partnership Access Programs

Companies are increasingly offering patient identification partnership programmes that provide subsidized comprehensive genomic profiling across an oncology center's full advanced cancer population, converting what was historically a one-time treatment procurement decision into recurring testing revenue tied directly to a center's screening expansion pace. Companies report identification partnership attach rates above 29% among oncology centers completing their first systematic screening programme, with renewal rates exceeding 74% once a center experiences a full screening cycle without an identification gap. This identification assurance increasingly determines vendor selection ahead of raw treatment pricing during center decisions.
Market Impact: Lifts recurring testing revenue to

Bundling Real-World Evidence and Clinical Support Services

Companies are increasingly bundling real-world evidence generation and clinical support services into treatment purchases, converting a previously separate research engagement into predictable recurring revenue while reducing the risk of an oncology center disengaging after treatment initiation without adequate outcomes tracking support. Bundled evidence support typically reduces a center's own data collection burden meaningfully during ongoing treatment cycles across departments nationwide. Companies report evidence support attach rates rising fastest among centers completing their first targeted therapy deployment, with roughly 25% of new customers now including bundled evidence support.
Market Impact: Cuts center evidence generation tim

Offering Multi-Site Testing Bundling and Standardization Programs

Companies with dedicated multi-site deployment infrastructure are increasingly offering bundled testing programmes that give oncology center networks a lower cost path to comprehensive genomic profiling standardization without negotiating individual panels separately for each facility served today. This bundled testing path typically reduces a network's per-facility profiling cost meaningfully compared with individual site panels, with bundled programmes now supporting roughly 21% of total new testing deployments completed annually across major oncology center networks. Companies report bundling attach rates rising fastest among networks seeking comprehensive multi-site standardization without significant per-facility investment burden.
Market Impact: Cuts network-wide testing cost by r

Structuring Multi-Region Access and Support Agreements

Companies are increasingly structuring multi-year access and support agreements that extend consistent treatment brand standards and pricing across an oncology network's entire regional facility footprint rather than negotiating each market independently, giving networks consistent treatment access standards across every operating location served today. Networks report cost of ownership reductions of roughly 16% once access standardization eliminates the redundant vendor management overhead multiple incompatible treatment brand standards previously required across the network. Companies with proven multi-region access track records spanning dozens of oncology markets are capturing outsized share of these agreements ahead of smaller competitors.
Market Impact: Cuts network-wide access cost by ro

Who Controls the Margin Pool

The top five companies hold roughly 71% combined share, a very high concentration reflecting both the substantial clinical trial and companion diagnostic partnership investment required for meaningful category participation and the proprietary mechanism barriers separating leading therapeutics developers from smaller regional producers. The gap between leading vendors and smaller developers is widening as oncology centers restrict shortlists to companies with demonstrated clinical evidence depth
Current competitive activity centers on three fronts: bispecific antibody expansion targeting tumor-agnostic demand, companion diagnostic partnership investment supporting broader patient identification, and multi-region access agreement development supporting broader oncology network reach. Several regional companies are pursuing partnerships with established diagnostic manufacturers rather than building internal companion diagnostic infrastructure independently, a faster but margin-diluting route to category participation.

Emerging pressure comes from Chinese and Indian biotechnology developers moving up the value chain from basic generic oncology formats into certified targeted and diagnostic systems sold initially to domestic oncology centers but increasingly targeting export markets as clinical credibility accumulates. Rankings among the top five could shift if a leader fails to close its diagnostic partnership or evidence gap, since oncology centers increasingly evaluate clinical depth ahead of price during treatment decisions.
rare-nrg1-fusion-market-company-positioning-matrix-1787309757013

Competitive Moat and Risk Dimensions

MERUS NV

Moat: Deep bispecific antibody portfolio

Merus's years of accumulated bispecific antibody clinical trial data and regulatory approval history give it durable credibility among oncology centers who weigh proven treatment efficacy evidence heavily, since qualifying a new targeted therapy brand without comparable clinical depth carries meaningful patient safety and reimbursement continuity risk. That credibility compounds with every additional trial result Merus publishes across new tumor categories.
MERUS NV

Risk: Narrow addressable patient population

Merus's reliance on an ultra-rare genomic alteration limits its total addressable patient population regardless of commercial execution quality, occasionally constraining revenue growth potential compared with therapeutics companies targeting more prevalent genomic alterations across broader oncology categories, larger patient populations, and more diversified indication portfolios.
FOUNDATION MEDICINE INC

Moat: Strong companion diagnostic testing depth

Foundation Medicine's long-standing investment in comprehensive genomic profiling and companion diagnostic validation technology gives it a design-in advantage with oncology centers seeking a partner that already understands complex biomarker testing nuance rather than building that expertise from scratch. That testing depth compounds with every additional validation study Foundation Medicine adds across new fusion categories.
FOUNDATION MEDICINE INC

Risk: Dependent on therapeutics partnerships

Foundation Medicine's diagnostic-only business model depends on therapeutics company partnerships to drive testing demand, occasionally limiting its ability to capture full category value compared with vertically integrated competitors combining diagnostic and treatment revenue streams within a single bundled commercial relationship.

Players Tracked

Prominent Players

Merus NV
Elevation Oncology Inc
Bicara Therapeutics Inc
Foundation Medicine Inc
Guardant Health Inc

Other Key Players

Daiichi Sankyo Company Limited
AstraZeneca plc
Pfizer Inc
Novartis AG
Eli Lilly and Company
Bristol Myers Squibb Company
Regeneron Pharmaceuticals Inc
Genentech Inc
Bayer AG
Boehringer Ingelheim GmbH
Tempus AI Inc
Caris Life Sciences Inc
NeoGenomics Inc
Exact Sciences Corporation
Illumina Inc

Recent Developments

MAY 2025

Merus Commissions New Bispecific Antibody Research Center

Merus commissioned a new dedicated bispecific antibody research center for clinical trial validation, adding meaningful research capacity to address surging demand from oncology centers requiring rapid response data across their expanding treatment programmes worldwide. The center also supports faster publication of new tumor category studies.
Signal: Confirms bispecific antibody research capa
AUGUST 2025

Foundation Medicine Signs Multi-Region Testing Agreement

Foundation Medicine signed a multi-year testing agreement with a major regional oncology center network, covering consistent companion diagnostic standards and direct facility access across dozens of affiliated cancer treatment locations nationwide. The agreement is a testing arrangement rather than a joint venture or acquisition, extending Foundation Medicine's multi-region presence considerably.
Signal: Highlights testing standardization bundlin
FEBRUARY 2026

AstraZeneca Acquires Regional Bispecific Antibody Developer

AstraZeneca completed the acquisition of a regional bispecific antibody developer, strengthening its NRG1 fusion treatment capability and expanding its ability to support oncology centers navigating rising tumor-agnostic treatment requirements across every major market worldwide today. The deal reinforces AstraZeneca's positioning across the broader rare NRG1 fusion market.
Signal: Signals continued consolidation of special

Biologic Manufacturing and Clinical Trial Cost Exposure

Biologic antibody manufacturing capacity and clinical trial execution costs together represent an estimated 42 to 52% of rare NRG1 fusion treatment cost of goods sold across most developers. Specialty biologic manufacturing capacity remains concentrated among a small number of qualified contract development and manufacturing organizations, creating a narrower supply base than most broader oncology categories rely upon for comparable production inputs.
Biologic manufacturing capacity price volatility during 2021 and 2022 raised production costs broadly, and several companies flagged the disruption in annual reports as a persistent cost pressure affecting multiple biologic therapeutics categories across the sector, per European Commission specialty biomanufacturing reporting. Several companies disclosed that manufacturing capacity constraints stretched development timelines beyond expected windows during the tightest period, forcing some smaller developers to delay launches or rely on costlier alternative manufacturing arrangements.

Smaller regional developers carry disproportionate exposure to these input swings since they lack the purchasing scale to negotiate multi-year fixed pricing directly with biologic manufacturing organizations that the top five companies secure more easily through established relationships. This gap is widest for developers dependent entirely on spot market manufacturing capacity, leaving them vulnerable to margin compression during input cost increases.
rare-nrg1-fusion-market-cost-volatility-analysis-1787309757208

Long-Term Biologic Manufacturing Supply Contracts

Leading companies now lock multi-year pricing directly with contract development and manufacturing organizations serving their primary biologic production needs, avoiding the spot market cost volatility that stretched development timelines during the 2021 to 2022 shortage and protecting launch schedules against disruption across major markets worldwide throughout sustained periods of biomanufacturing supply constraint industrywide.

Vertical Integration Into Biologic Manufacturing Capability

Top five companies increasingly build internal biologic manufacturing and antibody production capability rather than relying entirely on third-party contract manufacturers, smoothing development timelines and insulating treatment quality from the sourcing volatility smaller regional developers remain exposed to directly, a practice that has become standard operational policy since targeted therapy demand accelerated considerably across the industry.

Diversified Manufacturing Sourcing Across Multiple Suppliers

Companies without full vertical integration are increasingly qualifying multiple biologic manufacturing partners across different geographic regions, reducing exposure to any single supplier's capacity constraints or price swings and giving companies greater negotiating leverage during periodic manufacturing pricing renewal discussions spanning multiple continents, regulatory jurisdictions, and biomanufacturing producing regions served by their global development networks.

Portfolio Architecture for Margin Defence

Portfolio architecture splits across three tiers: entry priced companion diagnostic testing panels competing largely on volume, certified small molecule inhibitor systems carrying validation evidence value that commands a durable premium, and next generation bispecific antibody systems bundled with patient identification and evidence services. Margins widen meaningfully moving up this ladder as clinical evidence and companion diagnostic barriers concentrate hardest at entry.
The volume versus premium tension is sharpest in companion diagnostic testing, where laboratory competition has compressed prices fastest, pushing established companies to defend share through identification and evidence bundling rather than matching commodity pricing directly on testing volume alone. Bispecific antibody systems retain the strongest pricing power because clinical trial investment and multi-year evidence relationships discourage oncology centers from switching vendors mid-treatment, a dynamic strengthening as adoption broadens.

High value margin pools concentrate in bispecific antibody systems paired with continuous identification and evidence service contracts, where recurring testing revenue and high switching costs together support gross margins well above the portfolio average. Companies are prioritizing capital toward this tier even though it remains a minority of total treatment volume shipped across the broader portfolio today, betting the mix shifts decisively within the decade ahead.

Volume / Commodity-Adjacent Tier

Basic companion diagnostic testing panels competing primarily on volume against numerous regional laboratories, with limited service attach and thin per-test margins across most transactions and smaller oncology centers worldwide today.
Gross Margin: 20-28%

Premium / Certified Tier

Certified small molecule pan-HER inhibitor systems serving complex tumor-agnostic applications, where validation evidence depth and clinical support durable pricing power across the industry and every managed oncology center account served today.
Gross Margin: 40-48%

Sustainability / Regulatory / Next-Generation Tier

Bispecific antibody systems bundled with patient identification, evidence generation, and clinical support services, sold on recurring performance assurance value rather than volume pricing alone, increasingly the default specification for new investment.
Gross Margin: 54-62%
rare-nrg1-fusion-market-portfolio-architecture-1787309757709

High-value Sub-segments and Strategic Watch-out

Patient Identification and Evidence Generation Contracts

High value, high growth layer combining bispecific antibody attach with recurring identification and evidence service fees; margins scale directly with active oncology center screening volume and identification partnership intensity across large cancer center networks worldwide, rewarding companies investing earliest in identification and evidence capacity.
Gross Margin: 56-64%

Tumor-Agnostic Multi-Region Deployment Programs

High value, moderate growth segment tied to expanding tumor-agnostic approval demand, growing steadily as oncology networks commission multi-region targeted therapy programmes from first launch across major cancer treatment hub regions worldwide, currently expanding treatment capacity and evidence infrastructure to keep pace with rising deployment volume.
Gross Margin: 40-48%

Standard Companion Diagnostic Distribution Channels

Volume core segment generating steady recurring testing revenue from mid-sized oncology center networks requiring consistent panel supply across established genomic profiling configurations globally, reliably and predictably each year regardless of broader oncology pricing cycles affecting the wider industry and prevailing macroeconomic conditions worldwide today.
Gross Margin: 20-28%

Legacy Single-Gene Testing Adjacent Formats

Strategic watch out segment where declining oncology center preference and stable generic pricing limit growth further, requiring companies to defend remaining share through testing reliability rather than volume expansion into new oncology center markets facing continued substitution pressure from newer comprehensive-panel-enabled diagnostic classes worldwide today.
Gross Margin: 8-16%

Evidence Contracts Anchor Recurring Center Revenue

Rare NRG1 fusion economics function increasingly like an annuity once an identification relationship is established, since patient identification partnerships, real-world evidence services, and periodic treatment updates generate recurring revenue for years after the initial diagnostic contract closes. This recurring layer now represents a growing share of total category revenue and is the primary reason companies compete aggressively on initial oncology center acquisition even at thin entry tie
Adoption depth varies sharply by end use vertical. Large comprehensive cancer centers run near saturated genomic profiling coverage and generate mostly renewal and evidence demand, while smaller community oncology practices are still building out first time comprehensive testing coverage, generating a different mix of new customer acquisition revenue layered on the maturing testing base.

Buyer profiles are shifting generationally as younger technology-focused oncologists who expect comprehensive profiling and embedded evidence support increasingly influence category growth alongside veteran clinicians who remember when NRG1 fusion testing meant an incidental finding with no actionable treatment pathway available. This is accelerating demand for companies with strong identification capability even among oncology centers who historically evaluated diagnostics suppliers purely on testing cost and single-gene panel familiarity alone.
rare-nrg1-fusion-market-end-use-penetration-index-1787309758195

Where Treatment Strategy Should Focus

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CLINICAL EVIDENCE INVESTMENT

Prioritize response data depth over marginal pricing

Treatment pricing has become a secondary consideration across most large oncology center decisions, no longer the primary differentiator given rising expectations for validated clinical response data across every major tumor category. Oncology centers now evaluate clinical evidence depth and companion diagnostic reliability ahead of marginal price savings that once justified switching vendors on their own. Companies that continue competing primarily on standard treatment pricing risk losing share to evidence-focused rivals bundling clinical data, identification support, and diagnostics into a single recurring relationship that is harder to unwind once established.
02 / SERVICE MONETIZATION STRATEGY

Shift commercial models toward identification and evidence revenue

Standard companion diagnostic margins will keep compressing as regional laboratories gain share at the entry tier of the category across most emerging markets. Companies that convert patient identification partnerships, evidence generation support, and multi-site bundling into contracted recurring revenue will outperform peers still pricing primarily around one-time treatment sales alone. This shift also raises oncology center switching costs meaningfully, since replacing a treatment vendor requires displacing an entrenched, multi-year identification and evidence relationship built over years of accumulated clinical trust and historical response data.
03 / REGIONAL GROWTH PRIORITIZATION

Weight investment toward South Asia and East Asia over mature markets

South Asia and East Asia are compounding faster than Western Europe on both share and CAGR, driven by expanding genomic testing capacity investment, rising domestic oncology drug approval pathways, and first time treatment access across previously underserved regional cancer center networks. Companies weighting testing and evidence investment toward these regions ahead of competitors will capture a disproportionate share of new treatment deployment revenue. Mature markets, running mostly on renewal demand, simply cannot replicate that category of growth at comparable scale or rate over the coming decade of forecast activity.
04 / TESTING ACCESS EXPANSION RESPONSE

Expand community oncology testing programmes ahead of competitors

The gap between rising comprehensive genomic profiling awareness and available community oncology testing access represents a substantial growth opportunity that most companies are not yet equipped to capture efficiently given the specialized infrastructure investment required. Companies that invest early in dedicated community testing access programmes will be better positioned to capture broad patient identification accounts without the extended credibility-building timelines currently limiting some competitors. Companies ignoring this opportunity risk ceding identification-secured revenue to competitors who have already solved the community access problem.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Rare NRG1 Fusion Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Rare NRG1 Fusion Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a regional comprehensive cancer center operating advanced tumor testing across seven affiliated clinical facilities and multiple metropolitan markets, reporting annual precision oncology procurement spending in the tens of millions of dollars across its portfolio (client-reported, unverified by MMA). Its existing sourcing relied on fragmented single-gene testing protocols with inconsistent comprehensive profiling capability across its facility network.
STRATEGIC CHALLENGE
Facing rising demand for tumor-agnostic treatment identification and increasing competitive pressure from genomically-integrated peer cancer centers, clinical leadership sought to consolidate diagnostics vendor partnerships toward fewer comprehensive-panel-capable suppliers within twelve months, while avoiding any disruption to existing clinical workflow schedules across every active facility worldwide today, without exceeding budget.
MMA APPROACH
MMA benchmarked five candidate diagnostics vendor suppliers against companion diagnostic depth, clinical evidence reliability, and total cost of ownership over a five year horizon, then modeled consolidation sequencing to minimize clinical workflow disruption across the client's highest volume facilities during the phased vendor standardization programme currently under review by clinical leadership.
KEY FINDINGS
  1. Three of five candidate suppliers evaluated could not demonstrate consistent comprehensive genomic profiling coverage across all of the client's active clinical facilities reviewed.
  2. Consolidated diagnostics vendor procurement reduced projected annual precision oncology costs by 24% versus continued fragmented regional sourcing across comparable testing volumes, based on modeling completed during evaluation (client-reported, unverified by MMA).
  3. Centralizing companion diagnostic management was projected to cut technology operations administrative workload meaningfully across the client's regional facility network, according to internal operations modeling completed by the client.
  4. Facilities facing the most imminent tumor-agnostic demand growth carried the highest near term consolidation priority, reprioritizing the client's original sequencing considerably ahead of the initial twelve month plan.
CLIENT PROFILE
The client is a regional comprehensive cancer center operating advanced tumor testing across seven affiliated clinical facilities and multiple metropolitan markets, reporting annual precision oncology procurement spending in the tens of millions of dollars across its portfolio (client-reported, unverified by MMA). Its existing sourcing relied on fragmented single-gene testing protocols with inconsistent comprehensive profiling capability across its facility network.
STRATEGIC CHALLENGE
Facing rising demand for tumor-agnostic treatment identification and increasing competitive pressure from genomically-integrated peer cancer centers, clinical leadership sought to consolidate diagnostics vendor partnerships toward fewer comprehensive-panel-capable suppliers within twelve months, while avoiding any disruption to existing clinical workflow schedules across every active facility worldwide today, without exceeding budget.
MMA APPROACH
MMA benchmarked five candidate diagnostics vendor suppliers against companion diagnostic depth, clinical evidence reliability, and total cost of ownership over a five year horizon, then modeled consolidation sequencing to minimize clinical workflow disruption across the client's highest volume facilities during the phased vendor standardization programme currently under review by clinical leadership.
KEY FINDINGS
  1. Three of five candidate suppliers evaluated could not demonstrate consistent comprehensive genomic profiling coverage across all of the client's active clinical facilities reviewed.
  2. Consolidated diagnostics vendor procurement reduced projected annual precision oncology costs by 24% versus continued fragmented regional sourcing across comparable testing volumes, based on modeling completed during evaluation (client-reported, unverified by MMA).
  3. Centralizing companion diagnostic management was projected to cut technology operations administrative workload meaningfully across the client's regional facility network, according to internal operations modeling completed by the client.
  4. Facilities facing the most imminent tumor-agnostic demand growth carried the highest near term consolidation priority, reprioritizing the client's original sequencing considerably ahead of the initial twelve month plan.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1-4): Complete technical and clinical validation evaluation of the three highest-scoring candidate suppliers identified through careful independent review. Phase 2: Phase 2 (Months 5-9): Execute supplier consolidation across the highest volume clinical facilities in strict priority sequence today and beyond. Phase 3: Phase 3 (Months 10-12): Finalize network-wide vendor standardization and centralized identification validation dashboard fully enabled nationwide, with clinical leadership sign-off completed across every active site.
OUTCOME
The comprehensive cancer center completed vendor consolidation across all priority facilities within the twelve month window and reported meaningfully improved patient identification outcomes during subsequent internal reviews (client-reported, unverified by MMA). Clinical leadership gained centralized validation visibility previously unavailable across its distributed regional facility network and vendor partner base.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Rare NRG1 Fusion Market?

The global rare NRG1 fusion market reached an estimated $0.38 billion in 2025. Growth is driven by expanding comprehensive genomic profiling adoption and rising tumor-agnostic regulatory approval pathways worldwide.

How large will the Rare NRG1 Fusion Market be by 2036?

The market is projected to reach approximately $1.71 billion by 2036, roughly 3.89 times its 2026 value. Bispecific NRG1-HER3 targeted antibodies drive most of the added value across the category.

What is the CAGR for the Rare NRG1 Fusion Market 2026 to 2036?

The base case CAGR is 14.6% through 2036. Bull and bear scenarios range from roughly 13.1% to 15.9%, depending on genomic profiling adoption pace and regulatory approval speed.

Which segment is growing fastest?

Bispecific NRG1-HER3 targeted antibodies lead at a 21.5% CAGR, about 1.47x the overall market rate. Growth is concentrated among comprehensive cancer centers and academic oncology programmes.

Who are the major companies in the Rare NRG1 Fusion Market?

Merus, Elevation Oncology, Bicara Therapeutics, Foundation Medicine, and Guardant Health lead the category. Combined, the top five companies hold roughly 71% of global revenue on a consistent basis.

Which country is growing fastest?

China leads country level growth at an estimated 17.8% CAGR. Expanding genomic testing capacity and oncology drug approval pathways are driving demand across the region's clinical base.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Treatment Modality and Diagnostic Function

  • Bispecific NRG1-HER3 Targeted Antibodies
  • Small Molecule Pan-HER Inhibitors
  • Companion Diagnostic Testing Panels
  • Comprehensive Genomic Profiling Services
  • Patient Identification and Navigation Programmes
  • Clinical Trial and Real-World Evidence Services

By End-Use Care Setting

  • Comprehensive Cancer Centers
  • Academic Medical Centers
  • Community Oncology Practices
  • Reference and Central Laboratories

By Commercial Dimension

  • Direct Oncology Center Contracts
  • Payer and Health Plan Coverage Agreements
  • Multi-Site Deployment Agreements
  • Clinical Trial and Research Partnerships

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The rare NRG1 fusion market covers therapeutics, companion diagnostics, and clinical support services used to identify and treat cancers driven by neuregulin-1 gene fusion alterations, spanning bispecific NRG1-HER3 targeted antibodies, small molecule pan-HER inhibitors, companion diagnostic testing panels, comprehensive genomic profiling services, patient identification and navigation programmes, and clinical trial and real-world evidence services. Broad-spectrum chemotherapy and non-genomically targeted oncology treatments are excluded from market scope.
Quantitative Units
USD billions (current prices); identified patients treated where disclosed
Segmentation Dimensions
By Treatment Modality and Diagnostic Function; By End-Use Care Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Singapore, Thailand, Indonesia, UAE, Saudi Arabia, South Africa, Egypt, Turkey, Poland, Netherlands, Italy, Spain, Switzerland, Argentina, Colombia, Czech Republic, and additional markets relevant to this sector
Key Companies Profiled
Merus NV, Elevation Oncology Inc, Bicara Therapeutics Inc, Foundation Medicine Inc, Guardant Health Inc, Daiichi Sankyo Company Limited, AstraZeneca plc, Pfizer Inc, Novartis AG, Eli Lilly and Company, Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, Genentech Inc, Bayer AG, Boehringer Ingelheim GmbH, Tempus AI Inc, Caris Life Sciences Inc, NeoGenomics Inc, Exact Sciences Corporation, Illumina Inc
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-199
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Rare NRG1 Fusion Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the global rare NRG1 fusion market through 2036. It includes detailed segmentation by treatment modality, care setting, and commercial channel, alongside country level sizing across twenty-eight markets covering every major precision oncology demand center. Competitive profiles cover twenty companies with clinical evidence depth, companion diagnostic reach, and treatment benchmarking assessed on a consistent revenue basis. Buyers also receive access to the underlying primary survey and expert interview datasets referenced throughout the analysis, along with editable data tables.
Segment level CAGR and sizing tables
Regional and country level market breakdowns
Twenty company competitive profiles and benchmarks
Detailed clinical evidence benchmarking matrix for every profiled company
Input cost and supply chain risk analysis
Complete primary survey and expert interview datasets included

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts